3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
43
Neoplasms
13
Neoplasm Metastasis
8
Sarcoma
7
Carcinoma, Non-Small-Cell Lung
5
Triple Negative Breast Neoplasms
4
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms
2
Liposarcoma
2
Leiomyosarcoma
2
Inflammatory Breast Neoplasms
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasm, Residual
1
Metastatic Urothelial Cell Cancer
1
Lymphoma
1
Lung Neoplasms
1
Ketosis
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
Interventions
Sorafenib
52
pembrolizumab
26
Nivolumab
20
Bevacizumab
19
Radiosurgery
17
Doxorubicin
12
atezolizumab
9
Erlotinib Hydrochloride
9
lenvatinib
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
tremelimumab
6
durvalumab
6
Ramucirumab
6
Radiofrequency Ablation
6
Cisplatin
6
Sunitinib
5
tislelizumab
4
regorafenib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Everolimus
4
Capecitabine
4
nintedanib
3
fluoromisonidazole
3
carotuximab
3
bavituximab
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Hepatocellular
×
eribulin
×
Clear all
No trials found.